Drawing for SPHEROMED

USPTO serial 79065696

SPHEROMED

Reviewed by CopyMark Law Group

Reg. 3983391Status 404
Filing date
Status date
Registration date
Jun 28, 2011
Examiner
RIRIE, VERNA BETH
Law office
PUBLICATION AND ISSUE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with SPHEROMED?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Jeffrey A. Smith

Jeffrey A. Smith Millen, White, Zelano & Branigan, P.C.2200 Clarendon BoulevardSuite 1400Arlington, VA 22201

Goods and services

ClassDescriptionStatusFirst use
035Compilation and management of computerized databases; provision of business management information via computer databasesSECTION 71 - CANCELLED—
042Scientific and technological services and research and design, namely, database evaluation, design and development; computer diagnostic services; providing reagent sample testing and diagnostic services for others in the field of scientific research; diagnostic testing of humans for medical research purposes; medical research services; medical research in the field of oncology; medical research in the field of disease indications and identification of tumor indications; testing of drugs, biological and chemical preparations for medical research purposes; pharmaceutical research, inspection and development; pharmaceutical drug development services; medical and scientific research, namely, conducting clinical trials concerning biological and chemical preparations and pharmaceuticals; medical and scientific research, namely, researching profiles of biological and chemical preparations, pharmaceuticals, antigens; testing for scientific and medical research purposes of combinations of biological and chemical preparations and pharmaceuticals; testing for medical research purposes to determine the chemo-resistance and chemo-sensitivity of biological and chemical preparations and pharmaceuticals; medical research in the nature of testing the efficacy and toxicity of biological and chemical preparations and pharmaceuticals; medical research in the nature of testing the effects of biological and chemical preparations and pharmaceuticals on cell toxicity levels; medical research in the nature of pharmacokinetic testing of biological and chemical substances and known pharmaceuticals; medical research concerning the absorption, delivery, metabolism, excretion and toxicity testing of biological and chemical preparations and pharmaceuticals; medical and scientific research in the field of pharmaceuticals, genetic changes induced by biological or chemical preparations or pharmaceuticals, and pharmaceutical dosing levels; research and development of pharmaceutical treatment therapies for others; scientific research concerning tumor biology, progression and metastasis; medical research concerning optimal treatment and therapy regimes for individuals; medical research concerning optimal cancer therapy for individuals; research and development of new products for others in relation to prediction of cancer therapy; scientific and medical research in the field of radiotherapy; research, development and design of new radiotherapy products for others; scientific and medical research in the field of radio chemotherapy; research, development and design of new products for others in the field of radio chemotherapy; scientific and medical research in the field of stem cells and biomarker discovery, characterization and development; medical research in the fields of ex-vivo therapies, patient material profiling, tumor profiling, in vitro modeling of tissue and biological systems, tumor modeling, cell culture systems, three-dimensional cell culture systems, and three-dimensional culture of donor and patient cells; laboratory research services, namely, isolation, culture and treatment of donor and patient tissues and cells for medical research purposes; research laboratory services, namely, preparation of cell lines, primary tissues and fluids, and biological material into a format for scientific and medical research purposes; medical research concerning immunohistology, immunohistology preparation and investigation; research laboratory services, namely, creation and preparation of biological material into or onto a format for immunohistology investigation, creation and preparation of biological material on a solid or wax support, preparation of sections or slices of biological material on to slides, all for medical research purposes; medical research concerning small molecule development, preparation and generation, antibody research, development, preparation and generation, and vaccine research, development, preparation and generation; provision of information and data relating to scientific and technological research and development; provision of information and data relating to medical and veterinary research and development; provision of information and data relating to scientific and medical research concerning pharmaceuticals, drug testing, drug discovery and development, treatment and therapies, and testing of biological materialSECTION 71 - CANCELLED—
044Medical services; veterinary services; provision of information and data relating to pharmaceuticals, treatment and therapies, all relating to medical and veterinary fieldsSECTION 71 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
May 24, 2019DENCNOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG MAILED—
May 24, 2019DETHDEATH OF INTERNATIONAL REGISTRATION—
Dec 14, 2018INNTTOTAL INVALIDATION PROCESSED BY THE IB—
Oct 5, 2018INTSTOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB—
Oct 5, 2018INPCINVALIDATION PROCESSED—
Oct 2, 2018INTRTOTAL INVALIDATION OF REG EXT PROTECTION CREATED—
Feb 2, 2018C71TCANCELLED SECTION 71—
Mar 3, 2013FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Dec 2, 2011FICSFINAL DISPOSITION NOTICE SENT TO IB—
Dec 1, 2011FIMPFINAL DISPOSITION PROCESSED—
Sep 28, 2011FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Jun 28, 2011R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Apr 16, 2011OPNXNOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB—
Apr 12, 2011PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Mar 24, 2011OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Mar 24, 2011OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Mar 23, 2011NPUBNOTICE OF PUBLICATION—
Mar 9, 2011PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Mar 8, 2011CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Nov 4, 2010RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED—
Sep 3, 2010OPNXNOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB—
Aug 19, 2010OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Aug 19, 2010OPNRNOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB—
Apr 23, 2010RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED—
Oct 22, 2009CNSLLETTER OF SUSPENSION MAILED—
Oct 21, 2009CNSLSUSPENSION LETTER WRITTEN—
Sep 28, 2009TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Sep 28, 2009CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Sep 28, 2009ALIEASSIGNED TO LIE—
Sep 24, 2009TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 23, 2009ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 23, 2009REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Apr 23, 2009RFNTREFUSAL PROCESSED BY IB—
Mar 27, 2009RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Mar 27, 2009RFRRREFUSAL PROCESSED BY MPU—
Mar 27, 2009RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Mar 26, 2009CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 24, 2009MAFRAPPLICATION FILING RECEIPT MAILED—
Mar 20, 2009DOCKASSIGNED TO EXAMINER—
Mar 20, 2009NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Mar 19, 2009REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance